The -786C/T single-nucleotide polymorphism in the promoter of the gene for endothelial nitric oxide synthase: Insensitivity to physiologic stimuli as a risk factor for rheumatoid arthritis

Arthritis and Rheumatism

Volumn 54, Issue 10, 2006, Pages 3144-3151

  Melchers, Inga ^a   Blaschke, Sabine ^b   Hecker, Markus ^c   Cattaruzza, Marco ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF GÖTTINGEN   (Germany)

^c UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD40 ANTIGEN; CYTOKINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GENE PRODUCT; INTERLEUKIN 10; INTERLEUKIN 12; OLIGONUCLEOTIDE; PROTEIN NOS3; STAT3 PROTEIN; UNCLASSIFIED DRUG; NOS3 PROTEIN, HUMAN;

ADULT; AGED; ANIMAL CELL; ARTICLE; BLOOD SAMPLING; CELL CLONE; CELL ISOLATION; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CYTOKINE PRODUCTION; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE; GENE EXPRESSION REGULATION; GENE SEQUENCE; GENETIC VARIABILITY; GENOTYPE; HIGH RISK POPULATION; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; NOS3 GENE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; RISK FACTOR; SHEAR STRESS; SINGLE NUCLEOTIDE POLYMORPHISM; UMBILICAL ARTERY; CELL CULTURE; CELL LINE; CYTOLOGY; DRUG EFFECT; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; PHYSIOLOGY; VASCULAR ENDOTHELIUM;

ADULT; AGED; ANTIGENS, CD40; ARTHRITIS, RHEUMATOID; CELL LINE; CELLS, CULTURED; ENDOTHELIUM, VASCULAR; FEMALE; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; INTERLEUKIN-10; INTERLEUKIN-12; MALE; MIDDLE AGED; NITRIC OXIDE SYNTHASE TYPE III; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS (GENETICS); RISK FACTORS;

EID: 33750329097     PISSN: 00043591     EISSN: None     Source Type: Journal    
DOI: 10.1002/art.22147     Document Type: Article

References (40)

1. Cobb S, Anderson W, Bauer W. Length of life and cause of death in rheumatoid arthritis. N Engl J Med 1953;249:553-6.
2. Boers M, Dijkmans B, Gabriel S, Maradit-Kremers H, O'Dell J, Pincus T. Making an impact on mortality in rheumatoid arthritis: targeting cardiovascular comorbidity. Arthritis Rheum 2004;50: 1734-9.
3. Callahan LF, Pincus T. Mortality in the rheumatic diseases. Arthritis Care Res 1995;8:229-41.
4. Callahan LF, Pincus T, Huston JW III, Brooks RH, Nance EP Jr, Kaye JJ. Measures of activity and damage in rheumatoid arthritis: depiction of changes and prediction of mortality over five years. Arthritis Care Res 1997;10:381-94.
5. Wolfe F, Michaud K, Gefeller O, Choi HK. Predicting mortality in patients with rheumatoid arthritis. Arthritis Rheum 2003;48: 1530-42.
6. Snow MH, Mikuls TR. Rheumatoid arthritis and cardiovascular disease: the role of systemic inflammation and evolving strategies of prevention. Curr Opin Rheumatol 2005;17:234-41.
7. Wolfe F, Freundlich B, Straus WL. Increase in cardiovascular and cerebrovascular disease prevalence in rheumatoid arthritis. J Rheumatol 2003;30:36-40.
8. Pasceri V, Yeh ET. A tale of two diseases: atherosclerosis and rheumatoid arthritis. Circulation 1999;100:2124-6.
9. Ross R. Atherosclerosis: current understanding of mechanisms and future strategies in therapy. Transplant Proc 1993;25:2041-3.
10. Busse R, Fleming I. Endothelial dysfunction in atherosclerosis. J Vasc Res 1996;33:181-94.
11. Guzik TJ, Korbut R, Adamek-Guzik T. Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol 2003;54:469-87.
12. Cattaruzza M, Slodowski W, Stojakovic M, Krzesz R, Hecker M. Interleukin-10 induction of nitric-oxide synthase expression attenuates CD40-mediated interleukin-12 synthesis in human endothelial cells. J Biol Chem 2003;278:37874-80.
13. Cattaruzza M, Guzik TJ, Slodowski W, Pelvan A, Becker J, Halle M, et al. Shear stress insensitivity of endothelial nitric oxide synthase expression as a genetic risk factor for coronary heart disease. Circ Res 2004;95:841-7.
14. -786C endothelial nitric oxide synthase genotype is a novel risk factor for coronary artery disease in Caucasian patients of the GENICA study. J Am Coll Cardiol 2003;41:930-7.
15. Colombo MG, Paradossi U, Andreassi MG, Botto N, Manfredi S, Masetti S, et al. Endothelial nitric oxide synthase gene polymorphisms and risk of coronary artery disease. Clin Chem 2003;49: 389-95.
16. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
17. Morishita R, Higaki J, Tomita N, Ogihara T. Application of transcription factor "decoy" strategy as means of gene therapy and study of gene expression in cardiovascular disease. Circ Res 1998;82:1023-28.
18. Buchwald AB, Wagner AH, Webel C, Hecker M. Decoy oligodeoxynucleotide against activator protein-1 reduces neointimal proliferation after coronary angioplasty in hypercholesterolemic minipigs. J Am Coll Cardiol 2002;39:732-8.
19. Wagner S, Lynch NJ, Walter W, Schwaeble WJ, Loos M. Differential expression of the murine mannose-binding lectins A and C in lymphoid and nonlymphoid organs and tissues. J Immunol 2003;170:1462-5.
20. Haldane JB. An exact test for randomness of mating. J Genet 1954;52:631-5.
21. Guo SW, Thompson EA. Performing the exact test of Hardy-Weinberg proportions for multiple alleles. Biometrics 1992;48: 361-72.
22. Louis EJ, Dempster ER. An exact test for Hardy-Weinberg and multiple alleles. Biometrics 1987;43:805-911.
23. Raymond M, Rousset F. GENEPOP (version 1.2): population genetics software for exact tests and ecumenicism. J Heredity 1995;86:248-9.
24. Poirier O, Mao C, Mallet C, Nicaud V, Herrmann SM, Evans A, et al. Polymorphisms of the endothelial nitric oxide synthase gene - no consistent association with myocardial infarction in the ECTIM study. Eur J Clin Invest 1999;29:284-90.
25. Jeerooburkhan N, Jones LC, Bujac S, Cooper JA, Miller GJ, Vallance P, et al. Genetic and environmental determinants of plasma nitrogen oxides and risk of ischemic heart disease. Hypertension 2001;38:1054-61.
26. Ghilardi G, Biondi ML, DeMonti M, Bernini M, Turri O, Massaro F, et al. Independent risk factor for moderate to severe internal carotid artery stenosis: T786C mutation of the endothelial nitric oxide synthase gene. Clin Chem 2002;48:989-93.
27. Lacki JK, Klama K, Porawska W, Mackiewicz SH, Muller W, Wiktorowicz K. Interleukin 10 inhibits interleukin 6 production and acute phase response in rheumatoid arthritis. Arch Immunol Ther Exp 1995;43:11-4.
28. Van Roon JA, van Roy JL, Gmelig-Meyling FH, Lafeber FP, Bijlsma JW. Prevention and reversal of cartilage degradation in rheumatoid arthritis by interleukin-10 and interleukin-4. Arthritis Rheum 1996;39:829-35.
29. Asadullah K, Sterry W, Volk HD. Interleukin-10 therapy: review of a new approach. Pharmacol Rev 2003;55:241-69.
30. Narula K. Interleukin-10: a therapeutic cytokine for chronic inflammatory diseases. Curr Opin Anti-Inflam Immunomod Investig Drugs 2000;2:307-13.
31. -786T-→C mutation associated with coronary spastic angina. Hum Mol Genet 2000;9:2629-37.
32. Blackwell LJ, Borowiec JA. Human replication protein A binds single-stranded DNA in two distinct complexes. Mol Cell Biol 1994;14:3993-4001.
33. Quarcoo D, Weixler S, Groneberg D, Joachim R, Ahrens B, Wagner AH, et al. Inhibition of signal transducer and activator of transcription-1 attenuates allergen-induced airway inflammation and hyperreactivity. J Allergy Clin Immunol 2004;114:288-95.
34. Huckel M, Schurigt U, Wagner AH, Stockigt R, Petrow PK, Thoss K, et al. Attenuation of murine antigen-induced arthritis by treatment with a decoy oligodeoxynucleotide inhibiting signal transducer and activator of transcription-1 (STAT-1). Arthritis Res Ther 2005;8:R17. E-pub ahead of print.
35. Mann MJ, Whittemore AD, Donaldson MC, Belkin M, Conte MS, Polak JF, et al. Ex vivo gene therapy of human vascular bypass grafts with the E2F decoy: the PREVENT single-centre randomised clinical trial. Lancet 1999;354:1493-8.
36. Gonzalez-Gay MA, Llorca J, Sanchez E, Lopez-Nevot MA, Amoli MM, Garcia-Porrua C, et al. Inducible but not endothelial nitric oxide synthase polymorphism is associated with susceptibility to rheumatoid arthritis in northwest Spain. Rheumatology (Oxford) 2004;43:1182-5.
37. Firestein GS. Immunologic mechanisms in the pathogenesis of rheumatoid arthritis. J Clin Rheumatol 2005;11:S39-44.
38. Stehbens WE. The epidemiological relationship of hypercholesterolemia, hypertension, diabetes mellitus and obesity to coronary heart disease and atherogenesis. J Clin Epidemiol 1990;43:733-41.
39. Hakoda M, Oiwa H, Kasagi F, Masunari N, Yamada M, Suzuki G, et al. Mortality of rheumatoid arthritis in Japan: a longitudinal cohort study. Ann Rheum Dis 2005;64:1451-5.
40. -786→C mutation in the 5′-flanking region of the endothelial nitric oxide synthase gene is associated with coronary spasm. Circulation 1999;99:2864-70.